Phase 1 Multiple Ascending Dose Study of Elotuzumab (BMS-901608) in Combination With Lenalidomide/Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in Japan
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Assessment of safety and tolerability of Elotuzumab in combination with Lenalidomide and low dose Dexamethasone, based on the assessment of the Dose Limiting Toxicity (DLT) expression
Within the first 28 days
Yes
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Japan: Pharmaceuticals and Medical Devices Agency
CA204-005
NCT01241292
February 2011
September 2013
Name | Location |
---|